These findings showed that the ICAM1 expression level is correlated with malignancy in PCa patients and that PCa patients expressing lower levels of ICAM1 show higher malignancy and higher recurrence rates than those expressing higher levels of ICAM1. This evidence concerns the gene ICAM1 and posterior cortical atrophy.